I am an IP litigator and patent attorney helping clients achieve successful outcomes in their litigations, business deals, and IP strategies.

Kevin Shortsle focuses his practice on pharmaceutical, chemical, and medical device technologies, with additional focus on broader intellectual property litigation, licensing, diligence, patent prosecution, and counseling. Kevin helps clients navigate all aspects of patent litigation, from pre-filing investigations through trial and appeal. His recent representations include treatments for prostate cancer, schizophrenia, urea cycle disorders (UCDs), and Lambert-Eaton Myathenic Syndrome (LEMS), mRNA gene editing, reprogramming, and cell therapy, and a wide-range of sterile injectable formulations.

Kevin also prepares and negotiates licensing agreements and conducts due diligence assessments to support mergers and acquisitions. He also counsels clients and prepares opinions concerning patentability of inventions, validity of patents, and freedom-to-operate of pharmaceutical, chemical, surgical device, medical device, and food and beverage products and technologies.

Kevin is also well-versed in patent prosecution, having grown and managed several clients’ worldwide patent portfolios in a variety of subjects, including medical devices, diagnostic instrumentation, and food and beverage technologies.

+ View More


Intellectual Property

When ideas translate into products, processes, art, or authorship, we help clients protect their innovations and commercialize their work.



  • Chicago-Kent College of Law, 2008
    • J.D., Honors
  • University of Michigan, 2000
    • B.S., Chemical Engineering


  • Court of Appeals, Federal Circuit
  • U.S. District Court for the Northern District of Illinois
  • Supreme Court of Illinois
  • U.S. Patent and Trademark Office 


Representative Matters

  • Won Federal Circuit appeal upholding Massachusetts federal judge’s decision to overturn jury verdict for Perrigo, which Supreme Court subsequently denied certiorari.

  • Secured complete district court victory for Tolmar Therapeutics defending claims of patent infringement against its Eligard® product, an injectable treatment for prostate cancer.

  • Lead negotiations for global collaboration and licensing agreement for development of cell therapies using novel mRNA technologies.

  • Lead negotiations for global commercialization, collaboration, and licensing agreement for treatments related to Urea Cycle Disorders.

  • Achieved favorable settlement for Biomet in a 15-patent declaratory judgment action after Indiana federal judge allowed Biomet’s claims of inequitable conduct into the case.